Researchers have embarked on an early clinical trial testing a vaccine that targets one of Alzheimer's most notorious culprits.
The disease is characterised by the relentless deterioration of memory, judgement and the ability to live independently.
Much of that damage is attributed to tau, a protein that misfolds and accumulates within neurons, disrupting their normal function.
Rather than treating symptoms alone, the experimental vaccine seeks to mobilise the immune system to recognise and remove abnormal tau.
Crucially, this initial phase is designed to establish safety and tolerability over roughly a year, well before any question of efficacy can be settled.
The investigators are careful to temper expectations, emphasising that meaningful therapies remain years of rigorous testing away.
Even so, the effort sits within an unprecedented expansion of Alzheimer's research, fuelled by fresh funding and mounting scientific momentum.
For patients and caregivers confronting a disease with few effective options, that momentum is itself a meaningful source of optimism.